Skip to main content

Peer Review reports

From: A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

Original Submission
15 Feb 2020 Submitted Original manuscript
20 Mar 2020 Reviewed Reviewer Report - Michael Cordes
27 Apr 2020 Reviewed Reviewer Report - Rihan El Bezawy
11 May 2020 Author responded Author comments - Hamza Hasan
20 May 2020 Author responded Author comments - Hamza Hasan
Resubmission - Version 2
11 May 2020 Submitted Manuscript version 2
Publishing
25 May 2020 Editorially accepted
1 Jun 2020 Article published 10.1186/s12885-020-07000-2

You can find further information about peer review here.

Back to article page